These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 11129014)

  • 21. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.
    Li D; Ronson B; Guo M; Liu S; Bishop JS; Van Echo DA; O'Malley BW
    Cancer Res; 2002 Jul; 62(14):4023-8. PubMed ID: 12124336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas.
    Erlich RB; Rickwood D; Coman WB; Saunders NA; Guminski A
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):381-9. PubMed ID: 18398612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Radiotherapy combined with daily administration of low-dose cisplatin for squamous cell carcinomas of the head and neck].
    Hato N; Yumoto E; Hyodo M; Hinohira Y; Kawamura T; Fujii T
    Gan To Kagaku Ryoho; 1998 Aug; 25(10):1533-7. PubMed ID: 9725045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Feasibility and pharmacokinetics of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer.
    Aisner J; Belani CP; Kearns C; Conley B; Hiponia D; Engstrom C; Zuhowski E; Egorin MJ
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):17-21. PubMed ID: 7481856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Control of nodal metastases in squamous cell head and neck cancer treated by radiation therapy or chemoradiation.
    Vergeer MR; Doornaert P; Leemans CR; Buter J; Slotman BJ; Langendijk JA
    Radiother Oncol; 2006 Apr; 79(1):39-44. PubMed ID: 16632006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
    Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Scheduling cisplatin and radiotherapy in the treatment of squamous cell carcinomas of the head and neck: a modelling approach.
    Marcu L; Bezak E; Olver I
    Phys Med Biol; 2006 Aug; 51(15):3625-37. PubMed ID: 16861770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor.
    Mandic R; Rodgarkia-Dara CJ; Krohn V; Wiegand S; Grénman R; Werner JA
    Anticancer Res; 2009 Apr; 29(4):1181-7. PubMed ID: 19414362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemoradiation for advanced head and neck cancer: potential for improving results to match those of current treatment modalities for early-stage tumors--long-term results of hyperfractionated chemoradiation with carbogen breathing and anemia correction with erythropoietin.
    Villar A; Martinez JC; de Serdio JL
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1382-8. PubMed ID: 18037586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells.
    Masunaga S; Uto Y; Nagasawa H; Hori H; Nagata K; Suzuki M; Kinashi Y; Ono K
    Anticancer Res; 2006; 26(2A):1261-70. PubMed ID: 16619533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The comparison of weekly and three-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic squamous cell carcinoma of the head and neck.
    Uygun K; Bilici A; Karagol H; Caloglu M; Cicin I; Aksu G; Fayda M; Uzunoglu S
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):601-5. PubMed ID: 19123002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concomitant cisplatin, paclitaxel, and hyperfractionated radiotherapy in locally advanced head and neck cancer: comparison of two different schedules.
    Moreno-Jiménez M; Valero J; López-Picazo JM; Arbea L; Aristu J; Cambeiro M; Alcalde J; Martínez-Monge R
    Am J Clin Oncol; 2010 Apr; 33(2):137-43. PubMed ID: 19786847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer.
    Newlin HE; Amdur RJ; Riggs CE; Morris CG; Kirwan JM; Mendenhall WM
    Cancer; 2010 Oct; 116(19):4533-40. PubMed ID: 20572028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased cytotoxicity of squamous cell carcinoma of the head and neck by combining cisplatin with VP-16 and ciprofloxacin.
    Haller J; Burgess R; Dawson D
    Laryngoscope; 1993 Oct; 103(10):1081-3. PubMed ID: 8412441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head-and-neck squamous cell carcinoma.
    Nuyts S; Dirix P; Clement PM; Poorten VV; Delaere P; Schoenaers J; Hermans R; Van den Bogaert W
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1088-95. PubMed ID: 18707823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
    Rosen FR; Haraf DJ; Kies MS; Stenson K; Portugal L; List MA; Brockstein BE; Mittal BB; Rademaker AW; Witt ME; Pelzer H; Weichselbaum RR; Vokes EE
    Clin Cancer Res; 2003 May; 9(5):1689-97. PubMed ID: 12738722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intratumoral delivery of docetaxel enhances antitumor activity of Ad-p53 in murine head and neck cancer xenograft model.
    Yoo GH; Subramanian G; Ezzat WH; Tulunay OE; Tran VR; Lonardo F; Ensley JF; Kim H; Won J; Stevens T; Zumstein LA; Lin HS
    Am J Otolaryngol; 2010; 31(2):78-83. PubMed ID: 20015717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenografts.
    Skipper JB; McNally LR; Rosenthal EL; Wang W; Buchsbaum DJ
    ORL J Otorhinolaryngol Relat Spec; 2009; 71(1):1-5. PubMed ID: 18931526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.